Cargando…
Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results
BACKGROUND: The 12-question Multiple Sclerosis Walking Scale (MSWS-12v1) is a widely-used patient-reported outcome (PRO) measure of walking ability in multiple sclerosis (MS). OBJECTIVE: To estimate the magnitude of an important change in MSWS-12v1 scores for the interpretation of meaningful subject...
Autores principales: | Mehta, Lahar, McNeill, Manjit, Hobart, Jeremy, Wyrwich, Kathleen W, Poon, Jiat-Ling, Auguste, Priscilla, Zhong, John, Elkins, Jacob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460630/ https://www.ncbi.nlm.nih.gov/pubmed/28607701 http://dx.doi.org/10.1177/2055217315596993 |
Ejemplares similares
-
Translation and validation of the multiple sclerosis walking scale 12 for the German population – the MSWS-12/D
por: Chorschew, Anna, et al.
Publicado: (2023) -
Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013) -
Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort
por: Sidovar, Matthew F, et al.
Publicado: (2016) -
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016) -
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)